I'm LongbridgeAI, I can summarize articles.Mineralys Therapeutics CEO Jon Congleton sold 75,000 common shares on Sept. 30, 2026, at a weighted-average price of $25.4622 per share, totaling approximately $1.9 million. Following the transaction, his direct holdings decreased to 528,621 shares.
- Mineralys Therapeutics CEO Jon Congleton sold 75,000 common shares on Sept. 30, 2026. * Weighted-average sale price USD 25.4622 per share. * Direct holdings fell to 528,621 shares following the transaction. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001933414-26-000121), on October 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here